Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.66 |
| ▸ | CDK2 | P24941 | 4/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.46 |
| ▸ | YAP1 | P46937 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27589430 | 0.89 | CCNA2 (0.51) | CCNA2CDK2CDK5CDK5R1KDM4E | |
| SCHEMBL3384712 | 0.84 | CCNA2 (0.74) | CCNA2CDK2CDK5CDK5R1ALDH1A1 | |
| SCHEMBL6608787 | 0.83 | CDK5 (0.67) | CCNA2CDK2CDK5CDK5R1KDM4E | |
| SCHEMBL7385055 | 0.78 | PRMT5 (0.56) | PRMT5YAP1HTTALDH1A1 | |
| SCHEMBL6408297 | 0.78 | CDK2 (0.70) | CCNA2CDK2CDK5CDK5R1HTT | |
| SCHEMBL3388417 | 0.77 | CCNA2 (0.66) | CCNA2CDK2CDK5CDK5R1TP53 | |
| SCHEMBL6616475 | 0.77 | CDK5 (0.52) | CCNA2CDK2CDK5CDK5R1KDM4E | |
| SCHEMBL4469456 | 0.76 | CDK5 (0.71) | CCNA2CDK2CDK5CDK5R1KDM4E | |
| SCHEMBL7758141 | 0.76 | CCNA2 (0.76) | CCNA2CDK2CDK5CDK5R1GSK3A | |
| SCHEMBL3387481 | 0.74 | CDK5 (0.65) | CCNA2CDK2CDK5CDK5R1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | US | disclosed |
| EP-1417188-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | Novo Nordisk A/S (DK) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003011843-A1 | NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210063-A1 | Novel 2,4-diaminothiazole derivatives | GSK3B, GSK3A, GYS2 | CCNA2 3517/4885CDK2 507/4885PRMT5 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.